Time

Event

8:00 am – Lobby

Registration

9:45 am – 2nd Floor

Welcome Remarks
* Sara Jane Demy, Founder & CEO, Demy-Colton

10:00 am – 2nd Floor 

Fireside Chat
How AI will Change the Future of Healthcare, Genomic Medicine & Therapeutic Development

* Manolis Kellis, Professor, Computer Science, Computational Biology, Massachusetts Institute of Technology (MIT)
Introduced by Seema Kumar, CEO, Cure
Interviewed by David Ewing Duncan, Journalist, Author, Researcher

11:30 am – 12th Floor 

Dialogue 1A
The BioSecure Act: Balancing Security and Innovation in Biotechnology
The BioSecure Act is positioned as a landmark piece of legislation aimed at ensuring both security and innovation in this field. This panel will explore how the Act if passed by the Senate could shape future biotechnological endeavors, addressing national security, ethics, and the potential for innovation across biotech, manufacturing and pharma innovation.

Moderator: Virginia Amann, Founder, ENTENTE Network

Panel:
* Max Bayer, Pharma Reporter, Endpoints News
* Seth Flaum, Partner, Wilson Sonsini
* Greg Simon, President, Simonovation, LLC
* Arda Ural, Americas Life Sciences Leader, Ernst & Young LLP

11:30 am – Rooftop 

Dialogue 1B
Quantum Computing and Biology: The Convergence Reshaping the Future of Human Health

Moderator: Querida Anderson, Senior Editor, Healthcare, McKinsey Global Publishing

Panel:
* Wade Davis, VP, Computational Science & Head, Digital Research, Moderna (via Zoom)
* Alexey Galda, Associate Scientific Director, Quantum Algorithms & Applications, Moderna (via Zoom)
* Victoria Lipinska, Americas Lead for Quantum Innovation Centers, IBM

12:30 pm – 2nd Floor 

“Big Think" Plenary Session
Tackling the Hard Questions: Policy, PBMs, The IRA

Moderator: Jennifer Hawks Bland, CEO, NewYorkBIO

Panel:
* U.S. Congressman Jake Auchincloss, MA, 4th District
* Nouhad Husseini, SVP, Head of Business Development & Corporate Strategy, Regeneron Pharmaceuticals
* Philippe Lopes-Fernandes, Executive Vice President, Chief Business Officer, Ipsen
* Neal Masia, Co-Founder & CEO, EntityRisk
* Peter Rubin, Executive Director, No Patient Left Behind

1:45 pm – 12th Floor 

Luncheon

2:30 pm – 12th Floor

One-to-One Meetings

2:45 pm – 12th Floor

Presenting Companies

4:30 pm – 12th Floor 

Dialogue 2A
Pioneering Bioethics: Navigating the Frontiers of Cognitive Liberty, Privacy, and Innovative Therapeutics
This panel will examine the ethical implications of emerging neurotechnologies that can potentially alter or augment cognitive function, enhance brain-sensing technology, and diagnose disease. The panel will address the question of balancing privacy and innovation.

Moderator: Walter Greenleaf, Neuroscientist & Product Developer, Stanford University

Panel:
* Kurt Haggstrom, Chief Commercial Officer, Synchron
* Maite Malet, Investment & Corporate Development, Asabys Partners
* Brent Vaughan, Founder, Stealth TechBio

4:30 pm – Rooftop 

Dialogue 2B
New Frontiers in Autoimmune Disease: It’s Not What You Think
Autoimmune disease therapeutics are a particularly “hot” area in life sciences. Significant VC and strategic investments, R&D as well as M&A are driving substantial value creation in the area. What’s going on? Join us as we discuss with our panelists.

Moderator: Laurence Blumberg, Lecturer, Weill Cornell Medicine

Panel:
* David de Graaf, Co-Founder, CEO & President, Reverb Therapeutics
* Matthew Harrison, Global Head, Biotechnology Investment Banking, Morgan Stanley
* Lawrence Steinman, Zimmermann Professor of Neurology & Neurological Sciences, and Pediatrics, Beckman Center for Molecular Medicine, Stanford University (via Zoom)
* Geeta Vemuri, Founder & Managing Partner, Agent Capital

 

5:30 pm – 2nd Floor 

End of Day “Big Think” Plenary Session
Navigating New Horizons: Unlocking Opportunities in TechBio
The session will delve into the emerging opportunities in the TechBio sector, examining how technological advancements are revolutionizing biological research and applications including drug discovery tools, advances in personalized medicine, streamlining clinical trials and enhancing disease diagnosis and management. Panelists will discuss the current trends and future prospects in TechBio, investment strategies in this rapidly evolving field and the challenges and potential solutions in bringing TechBio innovations to market.

Moderator: Seth Flaum, Partner, Wilson Sonsini

Panel:
* Daniella Kranjac, Founding GP, Avant Bio
* Viq Pervaaz, Senior Vice President, New York City Economic Development Corporation
* Ajit Singh, Partner, Artiman Ventures